| Full Name | Shirley Rajan |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 19 Jay Road, Chatham, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902126816 | NPI | - | NPPES |
| Entity Name | Barnabas Health Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
Ashion Analytics LLC today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.
The composition of bacteria in the gastrointestinal tract may hold clues to help predict which cancer patients are most apt to benefit from the personalized cellular therapies that have shown unprecedented promise in the fight against hard-to-treat cancers, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.
UC San Francisco researchers have for the first time developed a method to precisely control embryonic stem cell differentiation with beams of light, enabling them to be transformed into neurons in response to a precise external cue.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
› Verified 4 days ago
| Entity Name | Princeton House Provider Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881078681 PECOS PAC ID: 0244540540 Enrollment ID: O20151116001851 |
News Archive
Ashion Analytics LLC today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.
The composition of bacteria in the gastrointestinal tract may hold clues to help predict which cancer patients are most apt to benefit from the personalized cellular therapies that have shown unprecedented promise in the fight against hard-to-treat cancers, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.
UC San Francisco researchers have for the first time developed a method to precisely control embryonic stem cell differentiation with beams of light, enabling them to be transformed into neurons in response to a precise external cue.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shirley Rajan, MD 4 Century Dr Ste 100, Parsippany, NJ 07054-4606 Ph: (732) 982-2888 | Shirley Rajan, MD 19 Jay Road, Chatham, NJ 07928 Ph: (973) 650-4998 |
News Archive
Ashion Analytics LLC today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.
The composition of bacteria in the gastrointestinal tract may hold clues to help predict which cancer patients are most apt to benefit from the personalized cellular therapies that have shown unprecedented promise in the fight against hard-to-treat cancers, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.
UC San Francisco researchers have for the first time developed a method to precisely control embryonic stem cell differentiation with beams of light, enabling them to be transformed into neurons in response to a precise external cue.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
› Verified 4 days ago
Elliott Gritz, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 52 Rolling Hill Dr, Chatham, NJ 07928 Phone: 973-886-1014 | |
Dr. Fernando Dangond, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 27 Dale Dr, Chatham, NJ 07928 Phone: 973-210-7327 | |
Dr. Seth Michael Dorsky, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 40 Main St Ste 7, Chatham, NJ 07928 Phone: 973-635-4244 Fax: 973-635-4246 | |
Dr. Joanna M Bird, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 10 Fairmount Ave, Chatham, NJ 07928 Phone: 973-822-0222 Fax: 973-822-0225 | |
Dr. Ernest Edward Dorflinger, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 10 Schindler Ct, Chatham, NJ 07928 Phone: 973-701-1732 |